# US 9,567,355 B2 · Hepatitis C inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,567,355 B2
- Document ID: US9567355B2
- Status: Granted
- Kind: B2
- Application number: 15/240,753
- Filed: 2016-08-18
- Published: 2016-12-08
- Granted: 2017-02-14
- Earliest claimed: 2010-12-22
- Assignees: AbbVie Inc.; Abbott Products GmbH
- Applicants: AbbVie Inc.; Abbott Products GmbH
- Inventors: Clarence J. Maring; John K. Pratt; William A. Carroll; Dachun Liu; David A. Betebenner; Douglas K. Hutchinson; Michael D. Tufano; Todd W. Rockway; Uwe Schoen; Axel Pahl; Andreas Witte
- Web page: https://patentgrep.com/patent/US9567355B2

## CPC

- C07F 7/1804: {Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896)}
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/4245: Oxadiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5395: having two or more nitrogen atoms in the same ring, e.g. oxadiazines
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/695: Silicon compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B65D 88/703: {Air blowing devices, i.e. devices for the sudden introduction of compressed air into the container}
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07F 9/65586: {at least one of the hetero rings does not contain nitrogen as ring hetero atom}
- F16K 31/363: the fluid acting on a piston (F16K31/38 takes precedence)
- Y10T 137/86405: Repeating cycle
- Y10T 137/86421: Variable
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B65D: CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- F16K: VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING {(devices for emptying and evacuating the excess liquid in valves or conduits F16L55/07)}
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

## Claims

### Claim 1

A compound having formula (I), or a pharmaceutically acceptable salt thereof,
wherein:
R1 is formula (v);
R1a, at each occurrence, is each independently hydrogen, halogen, C1-C3alkyl, or C1-C3haloalkyl;
R2 is C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, C1-C10haloalkyl, C2-C10haloalkenyl, C2-C10haloalkynyl, or L2A-G2a;
L2A is a bond, C2alkenylene, or C2alkynylene;
G2a is C6-C10aryl or 5- to 10-membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted with 1, 2, or 3 substituents selected from the group consisting of R20, L2B-R21, G2b and L2B-G2b;
L2B and L2C, at each occurrence, are each independently C1-C6alkylene, C2-C6alkenylene, or C2-C6alkynylene;
R20 is hydrogen, C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, C1-C10haloalkyl, C2-C10haloalkenyl, C2-C10haloalkynyl, halogen, —N(R2a)C(O)R2b, —C(O)N(R2a)(R2b), —O—R2b, —C(O)R2b, —OC(O)R2b, —CO2H, —CO2R2b, —N(R2a)C(O)N(R2a)(R2b), —S—R2b, —S(O)2R2b, —S(O)R2b, —SO2N(R2a)(R2b), —N(R2a)(R2b), —N(R2a)S(O)2R2b, N(R2a)C(O)O(R2b), or —C(═CH2)R2b;
R21 is —N(R2a)C(O)R2b, —C(O)N(R2a)(R2b), —O—R2b, —C(O)R2b, —OC(O)R2b, —CO2H, —CO2R2b, —N(R2a)C(O)N(R2a)(R2b), —S—R2b, —S(O)2R2b, —S(O)R2b, —SO2N(R2a)(R2b), —N(R2a)(R2b), —N(R2a)S(O)2R2b, N(R2a)C(O)O(R2b), or —C(═CH2)R2b;
R2a, at each occurrence, is each independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, or C3-C8cycloalkyl, wherein the C3-C8cycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, C1-C3alkyl, and C1-C3haloalkyl;
R2b, at each occurrence, is each independently hydrogen, C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, C1-C10haloalkyl, C2-C10haloalkenyl, C2-C10haloalkynyl, -L2C-R2c, G2b or -L2C-G2b;
R2c is —N(R2d)C(O)R2d, —C(O)N(R2d)(R2d), —O—R2d, —C(O)R2d, —OC(O)R2d, —CO2H, —CO2R2d, —N(R2d)C(O)N(R2d)(R2d), —S—R2d, —S(O)2R2d, —S(O)R2d, —SO2N(R2d)(R2d), —N(R2d)(R2d), —N(R2d)S(O)2R2d, or N(R2d)C(O)O(R2d);
R2d, at each occurrence, is each independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylene-OH, or C3-C8cycloalkyl, wherein the C3-C8cycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, C1-C3alkyl, and C1-C3haloalkyl;
G2b is C3-C10cycloalkyl, C5-C10cycloalkenyl, C6-C10aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G2b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, C1-C10haloalkyl, C2-C10haloalkenyl, C2-C10haloalkynyl, halogen, oxo, cyano, hydroxy, —O—C1-C6alkyl, —O—C1-C6haloalkyl, —C1-C3alkylene-O—H, —C1-C3alkylene-O—C1-C6alkyl, C(O)H, —C1-C3alkylene-NH2, —NH2, —NO2, —C(O)C1-C6alkyl, —C(O)OC1-C6alkyl, and G2c;
G2c is C6-C10aryl or 5- to 10-membered heteroaryl, wherein G2c is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, C1-C10haloalkyl, C2-C10haloalkenyl, C2-C10haloalkynyl, halogen, oxo, cyano, hydroxy, —O—C1-C6alkyl, —O—C1-C6haloalkyl, —C1-C3alkylene-O—H, —C1-C3alkylene-O—C1-C6alkyl, C(O)H, —C1-C3alkylene-NH2, —NH2, —NO2, —C(O)C1-C6alkyl, and —C(O)OC 1-C6alkyl;
A and B together are a bicyclic heteroaryl, wherein A is formula (vi) or formula (vii):
or
wherein,
V1 and V2 are each C, or one of V1 and V2 is N and the other is C, and V3 is CR7, NR7, N, O, or S; wherein, when A is (vii), V2 is C and V3 is N, O, or S;
R7 is hydrogen, C1-C3alkyl, C1-C3haloalkyl, or C3-C6cycloalkyl;
is a single or double bond;
W1 is N or CR6, W2 is N or CR5, W3 is N or CR4, and W4 is N or CR3, wherein none, one or two of W1, W2, W3 and W4 is N;
W5 is N or CR6, and W6 is N or CR5, wherein none or one of W5 and W6 is N;
W7 is N, O, or S;
R3 and R6 are each independently hydrogen, C1-C3alkyl, C1-C3haloalkyl, halogen, —OC1-C3alkyl, or —OC1-C3haloalkyl;
R4 is hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, —O—C6alkyl, —O—C1-C6haloalkyl, cyano, —NH2, L4A-OH, 5-membered heteroaryl optionally substituted with 1 or 2 alkyl or halogen, 5-membered heterocycle or —N(R40)(SO2R4a);
R40 is hydrogen, C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, C1-C10haloalkyl, C2-C10haloalkenyl, C2-C10haloalkynyl, C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -L4A-G4a, -L4A-C(O)-L4B-G4a, -L4A-O-L4B-G4a, -L4A-S(O)2-L4B-G4a, -L4A-N(R4b)(L4B-G4a), -L4A-N(R4b)C(O)-L4B-G4a, -L4A-N(R4b)S(O)2-L4B-G4a, or -L4A-R4c, wherein the C1-C10alkyl, C2-C10alkenyl, and C2-C10alkynyl are each optionally substituted with 2, 3, or 4 hydroxy substituents; and wherein the C3-C8cycloalkyl or 3- to 8-membered heterocyclyl is each optionally substituted with L4B-G4b and optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, C1-C3alkyl, C1-C3haloalkyl, —O—C1-C3alkyl, and —O—C1-C3haloalkyl;
L4A is C1-C10alkylene, C2-C10alkenylene, or C2-C10alkynylene, wherein L4A is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C1-C6alkyl, and C1-C6haloalkyl;
G4a is C3-C12cycloalkyl, C6-C12aryl, 3- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl, wherein G4a is optionally substituted with L4C-G4b and optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, C1-C3alkyl, C1-C3haloalkyl, —OH, —O—C1-C3alkyl, —O—C1-C3haloalkyl, thioxo, —NH2, —NH(C1-C3alkyl), and —N(C1-C3alkyl)2;
L4B and L4C, at each occurrence, are each independently a bond, C1-C6alkylene, C2-C6alkenylene, or C2-C6alkynylene, wherein L4B and L4C are each optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C1-C6alkyl, and C1-C6haloalkyl;
G4b is C3-C12cycloalkyl, 3- to 12-membered heterocyclyl, C6-C12aryl, or 5- to 12-membered heteroaryl, wherein G4b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, C1-C6alkyl, C1-C6haloalkyl, hydroxy, —O—C1-C6alkyl, —O—C1-C6haloalkyl, —S(O)—C1-C6alkyl, —S(O)2—C1-C6alkyl, —C(O)—C1-C6alkyl, C1-C3alkylene-OH, C1-C3alkylene-O—C1-C3alkyl, C1-C3alkylene-N(C1-C3alkyl)2, and C1-C3alkylene-(N-heterocyclyl);
R4a and R4b, at each occurrence, are each independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, or C3-C8cycloalkyl, wherein the C3-C8cycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, C1-C3alkyl, and C1-C3haloalkyl;
R4c is —O—R4b, —OC(O)R4b, —O—Si(C1-C6alkyl)3, —CN, —C(O)R4b, —CO2R4b, —C(O)N(R4b)2, —C(O)N(R4b)S(O)2R4b, —S—R4b, —S(O)2R4b, —S(O)R4b, —SO2N(R4b)2, —N(R4b)2, —N(R4b)C(O)R4b, —N(R4b)S(O)2R4b, —C(NOH)N(R4b)2, —C(O)C(OH)(R4b)2, or —P(O)(OR4b)2;
R5 is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, —O—C1-C6alkyl, —O—C1-C6haloalkyl, —O—C3-C6cycloalkyl, or G5a, wherein the C3-C6cycloalkyl groups are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, C1-C3alkyl, C1-C3haloalkyl, and oxo;
G5a is phenyl, wherein G5a is substituted with —C(O)N(R5a)-L5B-G5b, —C(O)-G5f, or —C(O)N(R5a)(R5e), and optionally substituted with 1, 2, or 3 substituents selected from the group consisting of C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, C1-C10haloalkyl, halogen, —O—R5b, CN, —N(R5b)C(O)R5b, —C(O)N(R5a)(R5b), —C(O)R5b, —OC(O)R5b, —CO2H, —CO2R5b, —N(R5b)C(O)N(R5a)(R5b), —S—R5b, —S(O)2R5b, —S(O)R5b, —SO2N(R5a)(R5b), —N(R5a)(R5b), —N(R5b)S(O)2R5b, N(R5b)C(O)O(R5b), -L5A-O—R5b, -L5A-CN, -L5A-N(R5b)C(O)R5b, -L5A-C(O)N(R5a)(R5b), -L5A-C(O)R5b, -L5A-OC(O)R5b, -L5A-CO2H, -L5A-CO2R5b, -L5A-N(R5b)C(O)N(R5a)(R5b), -L5A-S—R5b, -L5A-S(O)2R5b, -L5A-S(O)R5b, -L5A-SO2N(R5a)(R5b), -L5A-N(R5a)(R5b), -L5A-N(R5b)S(O)2R5b, -L5A-N(R5b)C(O)O(R5b), -G5d, and -L5A-G5d;
G5b is C3-C12cycloalkyl, C6-C12aryl, 3- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl, wherein each G5b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of oxo, halogen, C1-C6alkyl, C1-C6haloalkyl, —O—R5d, —CN, —N(R5d)C(O)R5d, —CON(R5a)(R5d), —C(O)R5d, —OC(O)R5d, —CO2H, —CO2R5d, —N(R5d)C(O)N(R5d)2, —S—R5d, —S(O)2R5d, —S(O)R5d, —SO2N(R5a)(R5d), —N(R5a)(R5d), —N(R5d)S(O)2R5d, N(R5d)C(O)O(R5d), -L5C-O—R5d, -L5C-CN, -L5C-N(R5d)C(O)R5d, -L5C-CON(R5a)(R5d), -L5C-C(O)R5d, -L5C-OC(O)R5d, -L5C-CO2H, -L5C-CO2R5d, -L5C-N(R5d)C(O)N(R5d)2, -L5C-S—R5d, -L5C-S(O)2R5d, -L5C-S(O)R5d, -L5C-SO2N(R5a)(R5d), -L5C-N(R5a)(R5d), -L5C-N(R5d)S(O)2R5d, -L5C-N(R5d)C(O)O(R5d), G5c, and -L5C-G5c;
G5c, at each occurrence, is each independently C3-C8cycloalkyl, C6-C10aryl, 4- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G5C is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, C1-C6alkyl, C1-C6haloalkyl, —O—C1-C6alkyl, and —O—C1-C6haloalkyl;
G5d, is at each occurrence, is each independently C3-C8cycloalkyl, C6-C10aryl, 4- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G5d is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of oxo, halogen, C1-C6alkyl, C1-C6haloalkyl, —O—R5d, —CN, —N(R5d)C(O)R5d, —CON(R5a)(R5d), —C(O)R5d, —OC(O)R5d, —CO2H, —CO2R5d, —N(R5d)C(O)N(R5d)2, —S—R5d, —S(O)2R5d, —S(O)R5d, —SO2N(R5a)(R5d), —N(R5a)(R5d), —N(R5d)S(O)2R5d, N(R5d)C(O)O(R5d), -L5C-O—R5d, -L5C-CN, -L5C-N(R5d)C(O)R5d, -L5C-CON(R5a)(R5d), -L5C-C(O)R5d, -L5C-OC(O)R5d, -L5C-CO2H, -L5C-CO2R5d, -L5C-N(R5d)C(O)N(R5d)2, -L5C-S—R5d, -L5C-S(O)2R5d, -L5C-S(O)R5d, -L5C-SO2N(R5a)(R5d), -L5C-N(R5a)(R5d), -L5C-N(R5d)S(O)2R5d, -L5C-N(R5d)C(O)O(R5d), G5c, and -L5C-G5c;
R5a, at each occurrence, is each independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, or C3-C8cycloalkyl, wherein the C3-C8cycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, C1-C3alkyl, and C1-C3haloalkyl;
R5b, at each occurrence, is each independently hydrogen, C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, C1-C10haloalkyl, -L5D-G5e, or -L5G-R5c;
R5c, at each occurrence, is each independently —CON(R5a)(R5g), —O—R5g, —OC(O)R5g, —CN, —C(O)R5g, —CO2H, —CO2R5g, —N(R5g)C(O)N(R5g)2, —S—R5g, —S(O)2R5g, —S(O)R5g, —SO2N(R5a)(R5g), —N(R5a)(R5g), —N(R5g)C(O)R5g, or —N(R5g)S(O)2R5g;
R5d, at each occurrence, is each independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, or -L5F-G5c;
R5e, at each occurrence, is each independently hydrogen, C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, C1-C10haloalkyl, or -L5E-R5f;
R5f is —CON(R5a)(R5d), —O—R5d, —OC(O)R5d, —CN, —C(O)R5d, —CO2H, —CO2R5d, —N(R5d)C(O)N(R5d)2, —S—R5d, —S(O)2R5d, —S(O)R5d, —SO2N(R5a)(R5d), —N(R5a)(R5d), —N(R5d)C(O)R5d, or —N(R5d)S(O)2R5d;
R5g is hydrogen, C1-C6alkyl, C1-C6haloalkyl, or -L5H-G5e;
G5e, at each occurrence, is each independently C3-C8cycloalkyl, C6-C10aryl, 4- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G5e is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, C1-C6alkyl, C1-C6haloalkyl, —OH, —O—C1-C6alkyl, and —O—C1-C6haloalkyl;
G5f is 4- to 10-membered heterocyclyl, wherein G5f is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, C1-C6alkyl, C1-C6haloalkyl, —O—C1-C6alkyl, and —O—C1-C6haloalkyl;
L5A, at each occurrence, is each independently C1-C6alkylene or C3-C8cycloalkyl, wherein L5A is each optionally substituted with 1, 2, 3, or 4 halogen;
L5B is a bond, C1-C6alkylene, or C3-C8cycloalkyl, wherein L5B is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
L5C, at each occurrence, is each independently C1-C6alkylene or C3-C8cycloalkyl, wherein L5C is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
L5D, at each occurrence, is each independently a bond, C1-C6alkylene, or C3-C8cycloalkyl, wherein L5D is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
L5E, at each occurrence, is each independently C1-C6alkylene, wherein L5E is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
L5F, at each occurrence, is each independently bond or C1-C6alkylene, wherein L5F is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
L5G, at each occurrence, is each independently C1-C6alkylene, wherein L5G is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy; and
L5H, at each occurrence, is each independently a bond, C1-C6alkylene, or C3-C8cycloalkyl, wherein L5H is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy.

### Claim 2 (depends on 1)

The compound or salt of claim 1, wherein:
R2 is L2A-G2a, wherein L2A is a bond;
R4 is hydrogen, —N(R40)(SO2R4a), or a 5-membered heteroaryl optionally substituted with 1 or 2 halogen or alkyl; and
R5 is hydrogen, C3-C6cycloalkyl, —O—C1-C6alkyl, or G5a, wherein the C3-C6cycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, C1-C3alkyl, C1-C3haloalkyl, and oxo.

### Claim 3 (depends on 2)

The compound or salt of claim 2, wherein:
V1 and V2 are each C;
V3 is O;
A is formula (vi);
W1 is CR6;
W2 is CR5;
W3 is CR4; and
W4 is CR3.

### Claim 4 (depends on 1)

The compound or salt of claim 1, wherein:
R2 is L2A-G2a, wherein L2A is a bond;
R4 is hydrogen, —N(R40)(SO2R4a), or a 5-membered heteroaryl optionally substituted with 1 or 2 halogen or alkyl;
R5 is hydrogen, C3-C6cycloalkyl, —O—C1-C6alkyl, or G5a, wherein the C3-C6cycloalkyl groups are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, C1-C3alkyl, C1-C3haloalkyl, and oxo:
V1 and V2 are each C, or V1 is C and V2 is N;
V3 is N or O;
A is formula (vi);
W1 is CR6;
W2 is CR5;
W3 is CR4; and
W4 is CR3.

### Claim 5 (depends on 4)

The compound or salt of claim 4, wherein:
G2a is phenyl, wherein the phenyl is optionally substituted with 1, 2, or 3 substituents selected from the group consisting of, R20, L2B-R21, G2b, and L2B G2b;
R4 is —N(R40)(SO2R4a);
V1 and V2 are each C; and
V3 is O.

### Claim 6

A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:
N-[5-cyclopropyl-2-(4-fluorophenyl)-3-(6-oxo-1,6-dihydropyrimidin-2-yl)-1-benzofuran-6-yl]-N-(3-methylbutyl)methanesulfonamide.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising one or more compounds of claim 1 or pharmaceutically acceptable salts thereof, one or more excipients; and optionally one or more additional therapeutic agents.

### Claim 8 (depends on 1)

A method of treating HCV infection, comprising administering a therapeutically effective amount of one or more compounds of claim 1 or pharmaceutically acceptable salts thereof, optionally in combination with one or more additional therapeutic agents.

### Claim 9 (depends on 8)

The method of claim 8, wherein the HCV infection is from an HCV virus of genotype 1a, 1b, 2a, 3a or 4a.

### Claim 10 (depends on 8)

The method of claim 8, wherein the HCV infection is from a mutant of an HCV virus.

### Claim 11 (depends on 1)

A method for inhibiting replication of an HCV virus, comprising exposing the virus to one or more compounds of claim 1 or pharmaceutically acceptable salts thereof, optionally in combination with one or more additional therapeutic agents.

### Claim 12 (depends on 6)

A pharmaceutical composition comprising the compound of claim 6 or a pharmaceutically acceptable salt thereof, one or more excipients; and optionally one or more additional therapeutic agents.

### Claim 13 (depends on 6)

A method of treating HCV infection comprising administering a therapeutically effective amount of the compound of claim 6 or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents.

### Claim 14 (depends on 13)

The method of claim 13, wherein the HCV infection is from an HCV virus of genotype 1a, 1b, 2a, 3a or 4a.

### Claim 15 (depends on 13)

The method of claim 13, wherein the HCV infection is from a mutant of an HCV virus.

### Claim 16 (depends on 6)

A method for inhibiting replication of an HCV virus, comprising exposing the virus to the compound of claim 6 or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents.